Recent advances in 1,3,5-triazine-based PI3K inhibitors for cancer therapy: a comprehensive review.

3-amino-1,2,4-triazine scaffolds as next-generation PDK inhibitors: Design, mechanistic insights, and efficacy in pancreatic ductal adenocarcinoma.

Overall, these results identify amino-triazine-based scaffolds as a promising new class of potent and selective PDK inhibitors with significant anticancer potential in pancreatic cancer.

Quinoxaline Derivatives As Anticancer Agents: Molecular Targets And SAR

Quinoxaline is a versatile nitrogen-containing heteroaromatic scaffold with considerable potential in anticancer drug discovery because structural modifications of its fused benzene–pyrazine framework can produce compounds with diverse pharmacological activities. This review highlights recent advances in the anticancer potential of quinoxaline derivatives, emphasizing their broad molecular targets and structure–activity relationships (SAR). Quinoxaline-based compounds have demonstrated activity against topoisomerases, tubulin, DNA repair pathways, PARP, histone deacetylases, folate metabolism, reactive oxygen species, VEGFR-2, EGFR, HER2, c-Met, PI3K/Akt/mTOR, PIM kinases, BRD9, BET proteins, PFKFB3, and apoptosis- and metastasis-associated pathways. SAR studies demonstrate that substitution pattern, aromaticity, hydrogen-bonding capacity, electronic properties, linker configuration, and physicochemical characteristics strongly influence anticancer potency and selectivity. Emerging approaches include selective targeting of BRD9 and BD1, inhibition of PFKFB3, VEGFR-2 blockade in treatment-resistant tumors, and modulation of HIF-1α, VEGF, and p21. Despite these advances, most quinoxaline-based anticancer candidates remain at the preclinical stage, with limitations involving inconsistent experimental conditions, inadequate pharmacokinetic characterization, poor aqueous solubility, metabolic instability, and potential off-target toxicity. Future development should therefore emphasize target validation, structure-based optimization, advanced drug-delivery approaches, pharmacokinetic improvement, physiologically relevant disease models, and rational combination strategies. Overall, quinoxaline represents a flexible platform for developing multifunctional and target-directed anticancer agents with potential applications across diverse cancer-associated pathways.

Isatin as a privileged scaffold for kinase inhibition: recent advances in anti-cancer research.

Protein kinases are key therapeutic targets in anticancer drug discovery due to their central roles in regulating cell proliferation, survival, and signaling pathways. Among diverse heterocyclic scaffolds, isatin (indole-2,3-dione) has emerged as a privileged framework for the development of potent kinase inhibitors due to its structural versatility and favorable interaction profile within binding pockets. This review provides a comprehensive overview of recent advances in isatin-based kinase inhibitors, highlighting their design strategies, structure-activity relationships (SAR), and key molecular determinants of potency and selectivity. Particular emphasis is placed on structural optimization at the N-1 and C-5/C-7 positions, as well as hybridization with heterocyclic pharmacophores has yielded compounds with nanomolar inhibitory activity against clinically relevant targets, including cyclin dependent kinases (CDKs), vascular-endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and other kinases. In addition, ligand-kinase interactions are critically analyzed, with focus on hinge-region hydrogen bonding and hydrophobic complementarity within the ATP-binding site. Computational approaches, including molecular docking studies, are integrated to rationalize binding modes and support SAR interpretations. Collectively, this review underscores isatin as a versatile and promising scaffold for the rational design of next generation multitarget kinase inhibitors with potential applications in anticancer therapy.

Tetrazole–imidazole hybrid derivatives as potential EGFR tyrosine kinase inhibitors: design, synthesis and in silico evaluation with preliminary antiproliferative assessment

VEGFR-2 as a druggable target: recent advances (2025) in the development of five-membered heterocyclic anticancer agents.

Mechanism and Molecular Target of Substituted Triazoles: A Therapeutic Strategy in Anticancer Drug Discovery.

Cancer remains a leading cause of mortality worldwide, necessitating the continuous discovery and development of novel therapeutic agents with improved efficacy and reduced toxicity. Heterocyclic compounds are privileged scaffolds in medicinal chemistry, and among them, the triazole ring system (1,2,3-triazoles and 1,2,4-triazoles) has emerged as a highly versatile and promising pharmacophore for anti-cancer drug discovery. This review is an attempt to bridge the gap between synthetic structural biology and translational oncology by systematically connecting the structure- activity relationships of novel triazole hybrids targeting Aromatase, VEGFR-2, IDO1, and Carbonic Anhydrase. We present a comprehensive overview of the recent advancements in the design, structure-activity relationships, and biological evaluation of triazole derivatives as potent anticancer agents. Triazoles are known to play an important role in modulating key oncogenic pathways (such as apoptosis induction, cell cycle arrest, angiogenesis inhibition, and metastasis suppression) by binding to various pharmacological targets. Here, we critically present the spatial configuration, such as the "tail approach" needed for carbonic anhydrase inhibition and the very specific heme-iron distances of the IDO1 pathway that govern the therapeutic promise. Clinical progress, toxicity, bioavailability, and resistance challenges have also been addressed. This review underscores the significance of triazole derivatives as multifunctional anticancer agents and provides insights into future directions for their development as targeted and potent chemotherapeutic agents. Although triazole derivatives are widely recognized as versatile, drug-like moieties, a critical research gap persists in understanding minor structural or electronic modifications near the triazole ring system to make the molecule target-specific and prevent liabilities due to non-selectivity.